Skip to content
Slynd – Healthcare Professionals Slynd – Healthcare Professionals
Order Slynd Samples Toggle full menu
Let's Love Every Body
Inclusive of Many Kinds of Bodies
Click Here to Learn More About: For Diverse Body Types and Health Considerations
Click Here to Learn More About: Manageable Bleeding Profile
Click Here to Learn More About: 24-Hour Missed Pill Window
Click Here to Learn More About: Active Ingredient Drospirenone

When the risk of estrogen is not worth taking, Zero in on Slynd®

Estrogen-free Slynd® is an option for many women who cannot or do not want to take estrogen-containing birth control1

An estrogen-free drospirenone formulation did not exist until 2019

• Like Combined Oral Contraceptives (COCs), Slynd® is effective with a familiar dosing regimen1

Missed Pill Window

Slynd® has a flexible 24-hour missed pill window.1,a This provides the window she needs to take Slynd® effectively.

Slynd’s 30-hour elimination half-life helps maintain therapeutic plasma levels.1

a Slynd® tablets must be taken every day at about the same time of the day so that the interval between two tablets is always 24 hours.

Slynd provides effective pregnancy prevention…1,a

a Efficacy was assessed in a single arm trial of 953 women 35 years or younger who were of reproductive potential.

4.0

PEARL INDEX1

(95% CI; 2.3, 6.4)

out of 5547 evaluable cycles

98.2%

Avoided pregnancy in clinical studies 1

1.8% Became pregnant

17 out of 953 females evaluated

332

b The data was insufficient to analyze Pearl Index by BMI subgroups

High BMI women included in the pivotal clinical trial 1,b

Mean BMI = 28.5 kg/m2

332 females BMI ≥ 30 (35%)
173 females had BMI ≥ 35 (18%)

Clinical Information

Slynd® was proven in clinical studies with over 3,400 women that it is a safe oral contraceptive8 and offers a convenient option for many telemedicine patients.

Slynd® does not require a blood pressure check prior to initiation.

Epidemiological studies have not indicated an association between estrogen-free preparations and an increased risk of myocardial infarction, cerebral thromboembolism, or venous thromboembolism.

No boxed warning!

Features of Slynd

Slynd® 24+4 Dosing Regimen

Slynd® has a familiar 24+4 dosing regimen that is similar to COCs8

Norethindrone Progestin-Only Pills (POPs) 9,a

28 pill dosing regimen
No placebo pills
a Brand name Micronor.

Slynd®

24+4 dosing regimen
24 active hormone pills + 4 placebo pills

Slynd® has a Manageable Bleeding Profile1,a

In clinical studies, over 13 cycles:

  • Breakthrough bleeding improved over time1
  • At cycle 12, 50.6% of subjects reported amenorrhea 2,b
  • Discontinuation rate due to bleeding irregularities was 3.5% of total subjects c

a In clinical studies, 3.5% of patients discontinued due to bleeding irregularities.

b No bleeding or spotting days reported during entire exposure cycle.

c A total of 91 out of 2593 subjects discontinued Slynd® due to menstrual bleeding disorders including metrorrhagia, menstrual irregular, vaginal hemorrhage, menorrhagia, uterine hemorrhage, and amenorrhea.

The active ingredient in Slynd® is drospirenone1

Drospirenone features include anti-androgenic and antimineralocorticoid activity1

  • Has no known androgenic activity
  • Associated with increased sodium excretion

a Table includes comparison of most commonly found progesterones in the US oral contraceptive market. Progestational Activity: Levonorgestrel 5.3, Norgestimate 1.3, Norethindrone 1.0, Drospirenone 1.5. Progestational and androgenic activity are relative to 1 mg dose of norethindrone.

The Slynd® pivotal trial included 39.2% of patients with 1 or 2 VTE risk factors1,2:

Thromboembolic Risk Factors (Among 1006 Patients Studied)

Why are
providers excited
about Slynd?

Dr. Alan Patterson

“Slynd is my number one pill because my patients love it! They appreciate the effects of drospirenone and the adjustment period is just a few months for them to get to a manageable bleeding profile.k And, best of all, I don’t get callbacks!”

kIn clinical studies, 3.5% of patients dropped out due to bleeding irregularities.

Dr. Julie Mullins

“A new patient came to me for her annual checkup; she was taking a combination birth control pill with 30mcg of estrogen. Given her smoking and hypertension, I suggested that she switch to Slynd. Now, over a year later, she’s still enjoying her experience with Slynd- highly effective contraceptive, low side effect profile, lighter periodsm. This is just one of many patient success stories I have had with Slynd!.”

mNot all patients will have the same experience, some patients will experience breakthrough, irregular or no periods.

Dr. Badeaux

Our office loves Slynd because it seems to work well in patients over 35 years old who smoke without carrying the estrogen-related riskI of potential increase in blood pressure and blood clots.

IUse of Slynd (drospirenone) in patients with a history of thromboembolic disorders has not been evaluated in clinical trials. Discontinue Slynd if a thromboembolic event occurs.

Resources

Learn important information about Slynd with this reference guide
Build dialogue with your patients using our quick facts document
Slynd Savings Card

Connect with our live medical educators

Connect

Order a Slynd sample

Order a sample

Savings Program

Download Copay Card

References

  • 1 Slynd package insert.
  • 2 Kimble T, et al. Contraception:X. 2020;2:100020.
  • 3 Parsey KS, Pong A. Contraception. 2000;61:105-111.
  • 4 Muhn P, et al. Contraception. 1995;51:99-110.
  • 5 Greer JB, et al. Obstet Gynecol. 2005;105:731-740.
  • 6 Louw-du Toit R, et al. Biochem Biophys Res Commun. 2020; 526 (6):466-471.
  • 7 Schindler AE, et al. Maturitas. 2003;4651:S7-S16.
  • 8 Data on file.
  • 9 Micronor package insert.

Slynd® Important Safety Information


Indication

SLYND (drospirenone) tablets are a progestin, indicated for females of reproductive potential to prevent pregnancy.

Contraindications

SLYND is contraindicated in females with renal impairment, adrenal insufficiency, a presence or history of cervical cancer or progestin sensitive cancers, liver tumors (benign or malignant) or hepatic impairment, and undiagnosed abnormal uterine bleeding.

Warnings and Precautions

Hyperkalemia: SLYND has anti-mineralocorticoid activity, including the potential for hyperkalemia in high-risk females. Check serum potassium levels prior to starting treatment and during the first treatment cycle in females receiving daily, long-term treatment for chronic conditions or diseases with medications that may increase serum potassium concentration. Consider monitoring serum potassium concentration in females at increased risk for hyperkalemia i.e., those females who take a strong CYP3A4 inhibitor long-term and concomitantly with SLYND. Monitor females taking SLYND who later develop conditions and/or begin medication that put them at an increased risk for hyperkalemia.

Thromboembolic Disorders: Epidemiological studies have not indicated an association between progestin-only preparations and an increased risk of myocardial infarction, cerebral thromboembolism, or venous thromboembolism. Consider the increased risk of thromboembolism inherent in the postpartum period and in females with a history of thromboembolism. Discontinue SLYND if a thromboembolic event occurs and consider discontinuing SLYND in case of prolonged immobilization due to surgery or illness.

Bone Loss: Treatment with SLYND leads to decreased estradiol serum levels. It is unknown if this may cause a clinically relevant loss of bone mineral density.

Liver Disease: Discontinue SLYND if jaundice or acute or chronic disturbances of liver function develop. Do not resume use until markers of liver function return to normal and SLYND causation has been excluded.

Ectopic Pregnancy: Be alert to the possibility of ectopic pregnancy in females who become pregnant or complain of lower abdominal pain while on SLYND.

Risk of Hyperglycemia in Patients with Diabetes: Females with diabetes may be at greater risk of hyperglycemia and may require additional medication adjustments or monitoring. Progestins, including SLYND, may decrease insulin sensitivity.

Bleeding Irregularities and Amenorrhea: Females may experience unscheduled (breakthrough or intracyclic) bleeding and spotting, especially during the first three months of use. If bleeding persists, occurs after previously regular cycles, or if scheduled bleeding does not occur, evaluate for possible causes such as pregnancy or malignancy.

Depression: Carefully observe females with a history of depression and discontinue SLYND if depression recurs to a serious degree. Data on the association of progestin-only contraceptive products with onset of depression and exacerbation of depression are limited.

The most common adverse reactions (>1%) are: acne, metrorrhagia, headache, breast pain, weight increased, dysmenorrhea, nausea, vaginal hemorrhage, decreased libido, breast tenderness, irregular menstruation.

Drug Interactions

Drugs or herbal products that induce certain enzymes (for example, CYP3A4) may decrease the effectiveness of SLYND® or increase breakthrough bleeding. Counsel patients to use a back-up or alternative non-hormonal method of contraception when enzyme inducers are used with SLYND and to continue back-up non-hormonal contraception for 28 days after discontinuing the enzyme inducer. Drugs or products that inhibit CYP3A4 may increase SLYND systemic exposure.

Slynd® Important Safety Information


Slynd does not protect against HIV infection (AIDS) and other sexually transmitted diseases (STDs).
What is Slynd? SLYND (drospirenone) tablets are a progestin, indicated for females of reproductive potential to prevent pregnancy.
SLYND is contraindicated in females with renal impairment, adrenal insufficiency, a presence or history of cervical cancer or progestin sensitive cancers, liver tumors (benign or malignant) or hepatic impairment, and undiagnosed abnormal uterine bleeding.

Are you a healthcare professional?

You are entering a page reserved for U.S. healthcare professionals only. By clicking on “Yes” below, you are confirming that you are a healthcare professional and wish to enter this page.

Yes, I am

If you are a Canadian healthcare professional, please visit slynd.ca

Go to slynd.ca

You're about to continue to our partner site

You are now leaving Slynd.com to visit a website that is not owned or operated by Exeltis USA, Inc. Links to outside sites are provided as a resource to our visitors and do not imply an endorsement or recommendation of a particular healthcare provide by Exeltis, nor an endorsement of any Exeltis product by any healthcare provider.

Exeltis accepts no responsibility or liability for the content or services of other websites. All prescription decisions are at the sole discretion of the healthcare provider based on each patient’s individual needs.

Proceed to Nurx